Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 5.4% - Should You Sell?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) was down 5.4% on Monday. The stock traded as low as $4.40 and last traded at $4.3810. 775,537 shares traded hands during trading, a decline of 74% from the average daily volume of 2,967,264 shares. The stock had previously closed at $4.63.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on TSHA shares. Robert W. Baird upped their target price on Taysha Gene Therapies from $12.00 to $15.00 and gave the stock an "outperform" rating in a report on Tuesday, June 30th. BMO Capital Markets boosted their price target on Taysha Gene Therapies from $10.00 to $14.00 and gave the stock an "outperform" rating in a report on Tuesday, June 23rd. The Goldman Sachs Group upped their price objective on Taysha Gene Therapies from $11.00 to $13.00 and gave the company a "buy" rating in a research note on Tuesday, July 21st. Pivotal Research set a $14.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, June 23rd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Taysha Gene Therapies in a report on Monday, September 21st. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Taysha Gene Therapies presently has an average rating of "Buy" and a consensus target price of $12.77.

Taysha Gene Therapies Trading Down 4.2%

The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.76 and a current ratio of 17.76. The firm's fifty day simple moving average is $5.62 and its 200-day simple moving average is $5.70. The stock has a market cap of $1.45 billion, a P/E ratio of -10.56 and a beta of 1.19.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). Equities research analysts expect that Taysha Gene Therapies, Inc. will post -0.52 EPS for the current fiscal year.

Insider Activity

In other news, insider Sukumar Nagendran sold 200,000 shares of the business's stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $6.24, for a total value of $1,248,000.00. Following the transaction, the insider directly owned 936,410 shares of the company's stock, valued at $5,843,198.40. The trade was a 17.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

Hedge funds have recently added to or reduced their stakes in the business. Arizona State Retirement System boosted its stake in shares of Taysha Gene Therapies by 5.4% during the 2nd quarter. Arizona State Retirement System now owns 39,633 shares of the company's stock valued at $270,000 after purchasing an additional 2,014 shares in the last quarter. Principal Financial Group Inc. boosted its position in Taysha Gene Therapies by 26.2% during the 1st quarter. Principal Financial Group Inc. now owns 16,185 shares of the company's stock valued at $72,000 after acquiring an additional 3,362 shares in the last quarter. Sei Investments Co. grew its holdings in shares of Taysha Gene Therapies by 7.6% during the 1st quarter. Sei Investments Co. now owns 51,472 shares of the company's stock worth $230,000 after acquiring an additional 3,614 shares during the period. Chicago Partners Investment Group LLC raised its position in shares of Taysha Gene Therapies by 2.5% in the 1st quarter. Chicago Partners Investment Group LLC now owns 170,751 shares of the company's stock worth $763,000 after acquiring an additional 4,210 shares in the last quarter. Finally, Cetera Investment Advisers raised its position in shares of Taysha Gene Therapies by 34.5% in the 1st quarter. Cetera Investment Advisers now owns 28,450 shares of the company's stock worth $127,000 after acquiring an additional 7,296 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system. The company uses adeno-associated virus-based delivery technologies and other genetic medicine approaches to target conditions with limited or no approved treatment options.

Taysha's research and development programs have included TSHA-102, an investigational gene therapy being developed for Rett syndrome, as well as programs for other rare neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.